PULIKE(SH:603566)2019-04-29 16:00Financial Performance - Net profit attributable to shareholders decreased by 62.6% year-on-year to CNY 14,418,319.35, primarily due to increased R&D expenses for major animal disease vaccines[11] - The company reported a basic earnings per share of CNY 0.04, a decrease of 66.67% compared to the same period last year[11] - Operating profit decreased to CNY 10,850,502.17 from CNY 42,623,908.55, a decline of approximately 74.6%[39] - Net profit for the quarter was CNY 14,418,319.35, down from CNY 38,551,260.14, indicating a decline of about 62.6%[41] - The company reported a total profit of CNY 16,260,625.51, down from CNY 44,358,843.71, indicating a decline of approximately 63.4%[39] Revenue and Sales - Revenue from pig vaccines decreased by 37.67% to CNY 32,186,350.04, impacted by a significant decline in pig inventory due to African swine fever[14] - Revenue from poultry vaccines and antibodies increased by 20.31% to CNY 55,153,219.96, indicating a positive trend in this segment[14] - Revenue from chemical drugs rose by 22.20% to CNY 55,567,473.39, reflecting strong performance in this category[14] - Total operating revenue for the first quarter was CNY 147,308,624.78, an increase from CNY 143,820,632.50 in the previous year, representing a growth of approximately 3.4%[39] Expenses and Costs - Operating cash flow net outflow increased by 282.98% year-on-year to CNY -48,393,711.45, mainly due to increased year-end bonuses and technical cooperation costs[14] - Total operating costs rose to CNY 139,725,241.76 from CNY 108,878,788.49, marking an increase of about 28.3%[39] - Research and development expenses surged by 170.69% to ¥32,121,004.20, primarily due to increased technical collaboration costs[20] - The company reported a significant increase in cash paid to employees, totaling CNY 54,232,936.27, up from CNY 40,387,468.11 year-over-year[50] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,883,129,230.75, a decrease of 1.05% compared to the end of the previous year[11] - The total number of shareholders at the end of the reporting period was 11,173[15] - Total liabilities decreased from ¥267,509,627.47 to ¥233,140,909.57, a reduction of approximately 12.8%[30] - Total equity increased from ¥1,635,570,001.83 to ¥1,649,988,321.18, reflecting a growth of about 0.9%[30] - Cash and cash equivalents decreased from ¥385,246,166.19 to ¥264,578,589.29, a decline of approximately 31.2%[33] Cash Flow - The net cash flow from operating activities decreased by 282.98% to -¥48,393,711.45, mainly due to the payment of last year's year-end bonuses and increased technical collaboration costs[20] - Cash inflow from operating activities totaled CNY 117,247,126.52, an increase from CNY 101,205,292.86 year-over-year[50] - Cash outflow from operating activities was CNY 165,640,837.97, compared to CNY 113,841,420.74 in the previous year, resulting in a net cash flow from operating activities of -CNY 48,393,711.45[50] Investments - The company's investment income plummeted by 88.48% to ¥699,792.26, attributed to reduced earnings from associated companies[20] - Investment income fell to CNY 699,792.26 from CNY 6,073,793.34, a decrease of approximately 88.5%[39] Shareholder Equity - The company's total owner's equity increased from ¥1,611,913,460.79 to ¥1,613,296,658.13, reflecting a growth of about 0.1%[34] - Unallocated profits increased from ¥750,669,278.57 to ¥765,087,597.92, an increase of approximately 1.7%[30] Other Financial Metrics - The weighted average return on net assets decreased by 1.52 percentage points to 0.88%[11] - The company's accounts receivable rose to ¥169,055,696.77, up from ¥146,623,662.04, indicating improved sales performance[25] - The company's other payables decreased slightly to ¥130,056,331.77 from ¥132,308,249.83, showing better cash management[28]